Skip to main content

Table 3 Factors affecting the response to 1st line therapy

From: Clinicopathologic features and therapy outcome in childhood Hodgkin’s lymphoma: a report from tertiary care center in Saudi Arabia

 

CR1 (n = 72)

Non-CR1 (n = 8)

P value

Age (years)

   < 5 years (n = 3)

3 (4.2%)

0 (0.0%)

0.118

  5–9.99 years (n = 23)

23 (31.9%)

0 (0.0%)

   ≥ 10 years (n = 54)

46 (63.9%)

8 (100.0%)

Gender

  Female (n = 35)

32 (44.4%)

3 (37.5%)

0.707

  Male (n = 45)

40 (55.6%)

5 (62.5%)

B symptoms

  No (n = 46)

44 (61.1%)

2 (25.0%)

0.050*

  Yes (n = 34)

28 (38.9%)

6 (75.0%)

Primary site

  Peripheral lymph nodes (n = 65)

58 (80.6%)

7 (87.5%)

0.286

  Mediastinum (n = 15)

14 (19.4%)

1 (12.5%)

Bulky

  No (n = 59)

52 (72.2%)

7 (87.5%)

0.351

  Yes (n = 21)

20 (27.8%)

1 (12.5%)

Extra nodal involvement

  No (n = 51)

48 (66.7%)

3 (37.5%)

0.104

  Yes (n = 29)

24 (33.3%)

5 (62.5%)

Pathology

  cHL, nodular sclerosis (n = 44)

39 (54.2%)

5 (62.5%)

0.395

  cHL, mixed cellularity (n = 18)

15 (20.8%)

3 (37.5%)

  cHL, lymphocyte rich (n = 9)

9 (12.5%)

0 (0.0%)

  NLPHL (n = 9)

9 (12.5%)

0 (0.0%)

Stage

  Early (I, II) (n = 30)

30 (41.7%)

0 (0.0%)

0.022*

  Advanced (III, IV) (n = 50)

42 (58.3%)

8 (100.0%)

Risk group

  Low (n = 12)

12 (16.7%)

0 (0.0%)

0.012*

  Intermediate (n = 44)

42 (58.3%)

2 (25.0%)

  High (n = 24)

18 (25.0%)

6 (75.0%)

  1. Data are expressed as number (%); p > 0.05 = not significant; p ≤ 0.05 = significant. CR1 complete remission after 1st line of therapy, Non-CR1 not in complete remission after 1st line of therapy, cHL classic Hodgkin’s lymphoma, NLPHL nodular lymphocyte predominant Hodgkin lymphoma